Jeena Sikho Lifecare Limited shares jumped more than 5% after the company announced that it has received approvals to conduct clinical trials on multiple products aimed at addressing diabetes, hypertension, constipation, and gastrointestinal health.
According to the company, the clinical and pre-clinical studies have shown encouraging results, with no adverse events reported. Key trials include:
-
Anti-Diabetes Efficacy of SDM02 Tablets: Pre-clinical study at MIET, Meerut demonstrated effectiveness in diabetic rats without any toxicity.
-
Shuddhi XS Syrup: Clinical trial on 60 patients at CCFT Laboratories, Meerut showed 92% relief in constipation and abdominal pain.
-
Petshuddhi Churna: Retrospective study on 100 patient records revealed improvement in bowel movement, stool consistency, and abdominal discomfort.
-
Shuddhi Dr. B P Care Tablets: Clinical trial on 60 hypertensive patients indicated significant reduction in blood pressure and heart rate within 2–3 hours, sustained up to 6 hours.
The company highlighted that these studies align with its strategy of scientific validation of Ayurvedic and herbal products to ensure efficacy and safety.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
